Draft:Bart Vanhaesebroeck
| Submission declined on 8 July 2024 by MicrobiologyMarcus (talk). The content of this submission includes material that does not meet Wikipedia's minimum standard for inline citations. Please cite your sources using footnotes. For instructions on how to do this, please see Referencing for beginners. Thank you.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: May meet WP:NPROF, review that page for more instructions on using citations to demonstrate WP:Notability. microbiologyMarcus [petri dish·growths] 16:11, 8 July 2024 (UTC)
Bart Vanhaesebroeck FRS[1] is a Belgian-UK scientist based at University College London. Vanhaesebroeck is Professor of Cell Signalling at the UCL Cancer Institute.
Career[edit]
Vanhesebroeck earned a licentiate in 1985 and a PhD in 1990, both from the University of Ghent. He then performed postdoctoral studies with Michael Waterfield at the Ludwig Institute for Cancer Research (London Branch) where he set up his independent research group in 1998. He became Professor at University College London in 2005 and Associate Member of the Ludwig Institute for Cancer Research in 2006. In 2007, he moved to Barts Cancer Institute at Queen Mary University of London to set up the Centre for Cell Signalling. In 2014, he became Professor of Cell Signalling at the UCL Cancer Institute.[2]
Research interests[edit]
Vanhaesebroeck's research team has made fundamental discoveries in the field of cell signalling by lipid second messengers, work which has led to approved medicines for leukemia.
Vanhaesebroeck’s contributions include uncovering the functions of PI 3-kinase (PI3K) family members[3] and the identification of PI3Kd,[4] the main PI3K in white blood cells, in which it controls immune functions.[5] His work has underpinned the generation of PI3Kd inhibitors that are currently used in the treatment of haematological malignancies and are being trialled in cancer immunotherapy of solid tumours.[6] [7] His team’s development of small molecule PI3K activators has opened new avenues for kinase drug development and their therapeutic applications.
Awards and honours[edit]
Vanhaesebroeck was elected as a Member of the European Molecular Biology Organisation (2012) and a Fellow of the Royal Society of Biology (2011), the Academy of Medical Sciences (2016) and the Royal Society (2024).[8]
See also[edit]
References[edit]
- ^ "Professor Bart Vanhaesebroeck FRS". Fellow Detail Page. Royal Society. Retrieved 9 July 2024.
- ^ "Bart Vanhaesebroeck". University College London. Retrieved 9 July 2024.
- ^ Vanhaesebroeck, Bart; Stephens, Len; Hawkins, Phillip (March 2012). "PI3K signalling: the path to discovery and understanding". Nature Reviews Molecular Cell Biology. 13 (3): 195–203. doi:10.1038/nrm3290. ISSN 1471-0072. PMID 22358332.
- ^ Vanhaesebroeck, Bart; Welham, Melanie J.; Kotani, Kei; Stein, Rob; Warne, Patricia H.; Zvelebil, Markéta J.; Higashi, Kyoichiro; Volinia, Stefano; Downward, Julian; Waterfield, Michael D. (29 April 1997). "p110δ, a novel phosphoinositide 3-kinase in leukocytes". Proceedings of the National Academy of Sciences. 94 (9): 4330–4335. Bibcode:1997PNAS...94.4330V. doi:10.1073/pnas.94.9.4330. ISSN 0027-8424. PMC 20722. PMID 9113989.
- ^ Okkenhaug, Klaus; Bilancio, Antonio; Farjot, Géraldine; Priddle, Helen; Sancho, Sara; Peskett, Emma; Pearce, Wayne; Meek, Stephen E.; Salpekar, Ashreena; Waterfield, Michael D.; Smith, Andrew J. H.; Vanhaesebroeck, Bart (9 August 2002). "Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice". Science. 297 (5583): 1031–1034. doi:10.1126/science.1073560. ISSN 0036-8075. PMID 12130661.
- ^ Ali, Khaled; Soond, Dalya R.; Piñeiro, Roberto; Hagemann, Thorsten; Pearce, Wayne; Lim, Ee Lyn; Bouabe, Hicham; Scudamore, Cheryl L.; Hancox, Timothy; Maecker, Heather; Friedman, Lori; Turner, Martin; Okkenhaug, Klaus; Vanhaesebroeck, Bart (19 June 2014). "Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer". Nature. 510 (7505): 407–411. Bibcode:2014Natur.510..407A. doi:10.1038/nature13444. ISSN 0028-0836. PMC 4501086. PMID 24919154.
- ^ Vanhaesebroeck, B; Roychoudhuri, R; Okkenhaug, K (2019). "PI3K inhibitors in cancer therapy: immune cells takes centre stage". Nat Rev Cancer.[failed verification]
- ^ Vanhaesebroeck, Bart (28 May 2024). "30 years of PI3K: an interview with Bart Vanhaesebroeck". Future Oncology: 1–4. doi:10.2217/fon-2024-0215. ISSN 1479-6694. PMID 38713423.
| International | |
|---|---|
| National | |
| Academics | |
| Other | |
